# TARGTEPO Treatment for Anemia in End Stage Renal Disease (ESRD) Patients Undergoing Peritoneal Dialysis (PD)

> **NCT02378662** · PHASE2 · TERMINATED · sponsor: **Aevi Genomic Medicine, LLC, a Cerecor company** · enrollment: 2 (actual)

## Conditions studied

- Anemia of End Stage Renal Disease

## Interventions

- **BIOLOGICAL:** MDGN201 TARGTEPO

## Key facts

- **NCT ID:** NCT02378662
- **Lead sponsor:** Aevi Genomic Medicine, LLC, a Cerecor company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-04
- **Primary completion:** 2016-01
- **Final completion:** 2016-06
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Sponsor's decision of the Early Termination of the study.
- **Last updated:** 2018-10-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02378662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02378662, "TARGTEPO Treatment for Anemia in End Stage Renal Disease (ESRD) Patients Undergoing Peritoneal Dialysis (PD)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02378662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*